Principal Consultant

Annemarie Ableitner-Kurz

Annemarie has been with NDA since 2007 and is an expert in the non-clinical development of new chemical entities, biotech and advanced medicinal products over a broad range of indications.

Key Areas Of Expertise
  • Scientific and regulatory strategy of non-clinical development programs (including pharmacology, pharmacokinetics and toxicology in vitro and in vivo studies) to support discovery, early and later stage clinical development for:
    • new chemical entities
    • biotech products (including biosimilars)
    • advanced therapeutic medicinal products
  • Risk assessments for first in man and later stages of clinical development
  • Due diligences for in-licensing / gap analyses of non-clinical data packages
  • Design, monitoring and evaluation of non-clinical studies/reports
  • Scientific, regulatory and operational support for interactions with regulatory agencies both in the EU and the US
  • Strategic and operational support for the preparation of both EU and US non-clinical regulatory documentation for clinical development (including pediatric development), MAA, BLA and NDA
Before NDA

Before joining NDA, Annemarie worked in the pharmaceutical industry in non-clinical development. Annemarie is a pharmacist with a PhD in Neuroscience and post educational training in pharmacology and toxicology.

Dr Annemarie Ableitner-Kurz

LinkedIn 

 

Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World